Clinical	B:C0037088
Features	I:C0037088
and	O
Complications	O
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
-	O
associated	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
:	O
A	O
Metanalysis	O
.	O

Clinical	O
Features	I:C0037088
and	O
Complications	B:C0009566
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
-	O
associated	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
:	O
A	O
Metanalysis	O
.	O

Clinical	O
Features	I:C0037088
and	O
Complications	O
of	O
the	O
HLA	B:C0019740
-	I:C0019740
B27	I:C0019740
-	O
associated	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
:	O
A	O
Metanalysis	O
.	O

Clinical	O
Features	I:C0037088
and	O
Complications	O
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
-	O
associated	O
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
:	O
A	O
Metanalysis	O
.	O

Clinical	O
Features	I:C0037088
and	O
Complications	O
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
-	O
associated	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
:	O
A	O
Metanalysis	B:C0920317
.	O

In	O
this	O
article	B:C1706852
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	B:C0023866
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	B:C0920317
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B:C0037088
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	B:C0019740
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	I:C0023866
based	I:C0023866
metanalysis	O
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	O
features	I:C0037088
of	O
the	O
HLA	O
-	I:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
(	O
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
)	O
.	O

The	O
examined	B:C0332128
material	O
was	O
based	O
on	O
observational	O
studies	I:C1518527
in	O
which	O
participants	O
were	O
affected	O
by	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	O
B27	I:C0587081
-	I:C0587081
.	O

The	O
examined	O
material	O
was	O
based	O
on	O
observational	B:C1518527
studies	I:C1518527
in	O
which	O
participants	O
were	O
affected	O
by	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	O
B27	I:C0587081
-	I:C0587081
.	O

The	O
examined	O
material	O
was	O
based	O
on	O
observational	O
studies	I:C1518527
in	O
which	O
participants	B:C0679646
were	O
affected	O
by	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	O
B27	I:C0587081
-	I:C0587081
.	O

The	O
examined	O
material	O
was	O
based	O
on	O
observational	O
studies	I:C1518527
in	O
which	O
participants	O
were	O
affected	O
by	O
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	O
B27	I:C0587081
-	I:C0587081
.	O

The	O
examined	O
material	O
was	O
based	O
on	O
observational	O
studies	I:C1518527
in	O
which	O
participants	O
were	O
affected	O
by	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	B:C0587081
B27	I:C0587081
-	I:C0587081
.	O

We	O
performed	O
a	O
search	O
on	O
articles	B:C1706852
with	O
the	O
words	O
"	O
HLA	O
B27	I:C0042164
uveitis	I:C0042164
"	O
dated	O
before	O
May	O
2014	O
.	O

We	O
performed	O
a	O
search	O
on	O
articles	O
with	O
the	O
words	O
"	O
HLA	B:C0042164
B27	I:C0042164
uveitis	I:C0042164
"	O
dated	O
before	O
May	O
2014	O
.	O

Among	O
these	O
,	O
29	O
articles	B:C1706852
were	O
selected	O
for	O
a	O
second	O
review	O
.	O

After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	B:C1706852
were	O
analyzed	O
.	O

After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	O
were	O
analyzed	B:C0936012
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	B:C0920317
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	B:C0442893
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	B:C0042812
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	B:C0020641
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	B:C0015982
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	B:C0234708
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	B:C0021888
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	B:C0021368
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	B:C0017601
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	B:C0152253
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	B:C0086543
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	B:C0024440
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	O
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	O
were	O
:	O
(	O
1	O
)	O
systemic	O
disease	I:C0442893
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	O
acuity	I:C0042812
;	O
(	O
5	O
)	O
hypopion	O
;	O
(	O
6	O
)	O
anterior	O
chamber	I:C0015982
's	I:C0015982
fibrin	I:C0015982
;	O
(	O
7	O
)	O
elevated	O
intraocular	I:C0234708
pressure	I:C0234708
(	O
intraocular	O
pressure	I:C0021888
)	O
during	O
inflammation	O
;	O
(	O
8	O
)	O
glaucoma	O
;	O
(	O
9	O
)	O
posterior	O
synechiae	I:C0152253
;	O
(	O
10	O
)	O
cataract	O
;	O
(	O
11	O
)	O
cystoid	O
macular	I:C0024440
edema	I:C0024440
;	O
(	O
12	O
)	O
papillitis	B:C0030353
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	B:C0019740
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	B:C0038013
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	B:C0442893
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	B:C0205092
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	B:C0238767
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	B:C0020641
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	B:C0033684
reaction	O
and	O
even	O
papillitis	O
(	O
R	O
=	O
7.7	O
)	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	O
B27	I:C0019740
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	O
spondylitis	I:C0038013
(	O
RR	O
=	O
6.80	O
)	O
and	O
systemic	O
diseases	I:C0442893
(	O
RR	O
=	O
9.9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1.2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1.1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2.2	O
)	O
involvement	O
,	O
hypopion	O
(	O
RR	O
=	O
5.5	O
)	O
,	O
fibrinous	O
reaction	O
and	O
even	O
papillitis	B:C0030353
(	O
R	O
=	O
7.7	O
)	O
.	O

Simultaneous	O
bilateral	B:C0238767
(	O
RR	O
=	O
0.3	O
)	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
is	O
more	O
frequent	O
in	O
HLA	O
-	I:C0019740
B27	I:C0019740
negative	O
form	O
.	O

Simultaneous	O
bilateral	O
(	O
RR	O
=	O
0.3	O
)	O
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
is	O
more	O
frequent	O
in	O
HLA	O
-	I:C0019740
B27	I:C0019740
negative	O
form	O
.	O

Simultaneous	O
bilateral	O
(	O
RR	O
=	O
0.3	O
)	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
is	O
more	O
frequent	O
in	O
HLA	B:C0019740
-	I:C0019740
B27	I:C0019740
negative	O
form	O
.	O

Simultaneous	O
bilateral	O
(	O
RR	O
=	O
0.3	O
)	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
is	O
more	O
frequent	O
in	O
HLA	O
-	I:C0019740
B27	I:C0019740
negative	B:C0205160
form	O
.	O

We	O
report	O
higher	O
risk	O
of	O
elevated	B:C0234708
IOP	I:C0234708
and	O
glaucoma	O
(	O
RR	O
=	O
0.6	O
)	O
in	O
B27	O
-	I:C0701807
Acute	I:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
.	O

We	O
report	O
higher	O
risk	O
of	O
elevated	O
IOP	I:C0234708
and	O
glaucoma	B:C0017601
(	O
RR	O
=	O
0.6	O
)	O
in	O
B27	O
-	I:C0701807
Acute	I:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
.	O

We	O
report	O
higher	O
risk	O
of	O
elevated	O
IOP	I:C0234708
and	O
glaucoma	O
(	O
RR	O
=	O
0.6	O
)	O
in	O
B27	B:C0701807
-	I:C0701807
Acute	I:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
.	O

No	O
significant	O
difference	O
between	O
HLA	B:C4285788
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	B:C0205160
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	B:C0701807
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	B:C0042812
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	B:C0009566
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	B:C0152253
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	B:C0086543
,	O
and	O
maculare	O
edema	I:C0024440
.	O

No	O
significant	O
difference	O
between	O
HLA	O
B	I:C4285788
27	I:C4285788
positive	I:C4285788
and	O
negative	O
Acute	O
Anterior	I:C0701807
Uveitis	I:C0701807
was	O
observed	O
according	O
to	O
final	O
visual	O
acuity	I:C0042812
and	O
complications	O
such	O
as	O
posterior	O
synechiae	I:C0152253
,	O
cataract	O
,	O
and	O
maculare	B:C0024440
edema	I:C0024440
.	O

We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B:C4084924
evaluation	I:C4084924
and	O
therapeutic	O
decision	O
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	O
condition	O
.	O

We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	O
evaluation	I:C4084924
and	O
therapeutic	O
decision	B:C0679006
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	O
condition	O
.	O

